Maruyama Wakae, Aoki Yasunobu
Research Center for Environmental Risk, National Institute for Environmental Studies, 16-2 Onogawa, Tsukuba 305-8506, Japan.
Toxicol Appl Pharmacol. 2006 Jul 15;214(2):188-98. doi: 10.1016/j.taap.2005.12.005. Epub 2006 Jan 27.
The health risk of dioxins and dioxin-like compounds to humans was analyzed quantitatively using experimental data and mathematical models. To quantify the toxicity of a mixture of three dioxin congeners, we calculated the new relative potencies (REPs) for 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), 1,2,3,7,8-pentachlorodibenzo-p-dioxin (PeCDD), and 2,3,4,7,8- pentachlorodibenzofuran (PeCDF), focusing on their tumor promotion activity. We applied a liver foci formation assay to female SD rats after repeated oral administration of dioxins. The REP of dioxin for a rat was determined using dioxin concentration and the number of the foci in rat liver. A physiologically based pharmacokinetic model (PBPK model) was used for interspecies extrapolation targeting on dioxin concentration in liver. Toxic dose for human was determined by back-estimation with a human PBPK model, assuming that the same concentration in the target tissue may cause the same level of effect in rats and humans, and the REP for human was determined by the toxic dose obtained. The calculated REPs for TCDD, PeCDD, and PeCDF were 1.0, 0.34, and 0.05 for rats, respectively, and the REPs for humans were almost the same as those for rats. These values were different from the toxic equivalency factors (TEFs) presented previously (Van den Berg, M., Birnbaum, L., Bosveld, A.T.C., Brunstrom, B., Cook, P., Feeley, M., Giesy, J.P., Hanberg, A., Hasegawa, R., Kennedy, S.W., Kubiak, T., Larsen, J.C., Rolaf van Leeuwen, F.X., Liem, A.K.D., Nolt, C., Peterson, R.E., Poellinger. L., Safe, S., Schrenk, D., Tillitt, D, Tysklind, M., Younes, M., Waern, F., Zacharewski, T., 1998. Toxic equivalency factors (TEFs) for PCBs, PCDDs, PCDFs for humans and wildlife. Environ. Health Perspect. 106, 775-792). The relative risk of excess liver cancer for Japanese people in general was 1.7-6.5 x 10(-7) by TCDD only, and 2.9-11 x 10(-7) by the three dioxins at the present level of contamination.
利用实验数据和数学模型对二噁英及类二噁英化合物对人类的健康风险进行了定量分析。为了量化三种二噁英同系物混合物的毒性,我们计算了2,3,7,8-四氯二苯并-对-二噁英(TCDD)、1,2,3,7,8-五氯二苯并-对-二噁英(PeCDD)和2,3,4,7,8-五氯二苯并呋喃(PeCDF)的新相对效力(REPs),重点关注它们的肿瘤促进活性。在对雌性SD大鼠反复口服二噁英后,我们应用肝脏病灶形成试验。根据二噁英浓度和大鼠肝脏中的病灶数量确定大鼠二噁英的REP。基于生理学的药代动力学模型(PBPK模型)用于以肝脏中二噁英浓度为目标的种间外推。通过用人PBPK模型进行反向估计来确定人类的毒性剂量,假设靶组织中相同的浓度可能在大鼠和人类中引起相同水平的效应,并根据获得的毒性剂量确定人类的REP。计算得出,TCDD、PeCDD和PeCDF对大鼠的REP分别为1.0、0.34和0.05,对人类的REP与对大鼠的几乎相同。这些值与之前公布的毒性当量因子(TEFs)不同(Van den Berg, M., Birnbaum, L., Bosveld, A.T.C., Brunstrom, B., Cook, P., Feeley, M., Giesy, J.P., Hanberg, A., Hasegawa, R., Kennedy, S.W., Kubiak, T., Larsen, J.C., Rolaf van Leeuwen, F.X., Liem, A.K.D., Nolt, C., Peterson, R.E., Poellinger. L., Safe, S., Schrenk, D., Tillitt, D, Tysklind, M., Younes, M., Waern, F., Zacharewski, T., 1998. Toxic equivalency factors (TEFs) for PCBs, PCDDs, PCDFs for humans and wildlife. Environ. Health Perspect. 106, 775 - 792)。仅TCDD时,日本普通人群患肝癌的额外相对风险为1.7 - 6.5×10⁻⁷,在当前污染水平下,三种二噁英导致的额外相对风险为2.9 - 11×10⁻⁷。